[A17-52] Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V

Last updated 04.01.2018

Project no.:
A17-52

Commission:
Commission awarded on 29.09.2017 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adult patients with locally advanced or metastatic urothelial carcinoma after pretreatment with platinum-based chemotherapy (second-line treatment)

Result of dossier assessment:

Hint of a considerable added benefit

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

04.01.2018

Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: Studies of direct comparison are useful

Four dossier assessments involving comparisons between immunotherapies and chemotherapies for the same therapeutic indication...

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2018-08-02 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.